Filter Results:
(624)
Show Results For
- All HBS Web
(624)
- People (2)
- News (57)
- Research (449)
- Events (2)
- Multimedia (8)
- Faculty Publications (395)
Show Results For
- All HBS Web
(624)
- People (2)
- News (57)
- Research (449)
- Events (2)
- Multimedia (8)
- Faculty Publications (395)
- November 2009
- Case
The Explosion of Genetic Testing: Opportunities and Challenges
By: Richard G. Hamermesh, Mara G. Aspinall and Rachel Gordon
This case study invites the reader to consider genetic testing in several different lights. First, can the business of genetic testing be considered a disruptive innovation to the current drug therapy model as defined by Harvard Business School Professor Clay... View Details
- October 2009 (Revised July 2013)
- Case
Gilead Sciences, Inc.: Access Program
By: V. Kasturi Rangan and Katharine Lee
Gilead Sciences, the U.S. leader in HIV/AIDS medicines, with global sales of $5.4 billion in 2009, had undertaken several innovative actions to make its anti-viral products available to over 100 low- and middle-income countries. Having reached nearly 680,000 patients... View Details
Keywords: Health Care and Treatment; Emerging Markets; Product; Sales; Competitive Strategy; Biotechnology Industry; Biotechnology Industry
Rangan, V. Kasturi, and Katharine Lee. "Gilead Sciences, Inc.: Access Program." Harvard Business School Case 510-029, October 2009. (Revised July 2013.)
- June 2008
- Case
Gordon Williams: Clinical Research at Brigham and Women's Hospital
By: H. Kent Bowen and Courtney Purrington
Clinical research is a critical element of biomedical research and development. This case describes the challenges of clinical research, and its role in bringing breakthroughs to patients. Dr. Williams leads through his own research and special programs to train... View Details
Keywords: Training; Health Care and Treatment; Success; Programs; Research and Development; Biotechnology Industry; Biotechnology Industry
Bowen, H. Kent, and Courtney Purrington. "Gordon Williams: Clinical Research at Brigham and Women's Hospital." Harvard Business School Case 608-168, June 2008.
- June 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (D)
By: Sandra J. Sucher and Stacy McManus
Supplements the (A) and (B) cases. View Details
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (D)." Harvard Business School Case 603-046, June 2003. (Revised October 2004.)
- 26 Jun 2000
- Research & Ideas
Presentation Round-Up
recently joined with the private company Celera Genomics to announce the cracking of the human genetic code.) Increasing interest in such research has led to complex legal tangles. Patent attorney Brenda Herschbach Jarrell of Choate, Hall & Stewart, who specializes... View Details
- 01 Dec 2004
- News
The Future of Stem Cells
sickle cell anemia.) A board member and former chair of the Massachusetts Biotechnology Council, Fisher says states are stepping up to fund stem-cell work, partly in response to their constituents who want the jobs and businesses — as... View Details
Keywords: Garry Emmons
- 05 Aug 2014
- First Look
First Look: August 5
Case 614-063 Merrimack Pharmaceuticals, Inc. (A) In 2006, Merrimack Pharmaceuticals was a fast-growing biotechnology company. Its leadership team was divided over whether to keep R&D organized in functional departments or transition... View Details
Keywords: Sean Silverthorne
- 01 Oct 2000
- News
The Entrepreneurial Venture
surprising that the venture capital industry was essentially dormant at the time. But with the growth of the microprocessor and of biotechnology in the late 1970s, as well as the deregulation of the airline and financial services... View Details
- 01 Nov 2024
- In Practice
Layoffs Surging in a Strong Economy? Advice for Navigating Uncertain Times
decision about entrepreneurship Starting your own company after a layoff is a significant decision. While it may seem like an opportune time, research suggests there are some important considerations. “Entrepreneurs coming from high-tech sectors such as View Details
- 16 Jun 2003
- Research & Ideas
Surveying the VC Landscape
public within five to seven years of its initial financing, will be able to pursue research that will not have a payoff for fifteen, twenty, or even more years in the future. (But it's not impossible—after all, venture capital has played a key role in the financing of... View Details
- September 1989 (Revised December 1989)
- Case
Beef Hormone Trade Dispute
By: Ray A. Goldberg
Keywords: Trade; Agribusiness; Food; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry
Goldberg, Ray A. "Beef Hormone Trade Dispute." Harvard Business School Case 590-035, September 1989. (Revised December 1989.)
- 06 Oct 2020
- Blog Post
2+2 Where Are They Now Spotlight: Curtis Wu (MBA 2018)
Can you describe your role?I currently work at Amgen Inc at their global HQ in Southern California. Amgen is the largest independent biotechnology company in the world by revenue and our top medicines include autoimmune drug Enbrel, white... View Details
- 01 Aug 2002
- News
For Alumni Only: Breakthrough Insights Program Debuts
case on the biotechnology firm Biogen, where a seemingly innocuous decision to license databases of new proteins discovered through genomic research wound up completely transforming the company's product-development process. As Vietor led... View Details
Keywords: Laura Singleton
- 09 Apr 2012
- Research & Ideas
Who Sways the USDA on GMO Approvals?
Many corporations have gotten good at pulling the levers of government to tilt the odds in their favor, weakening regulations or securing perks, justified or not, to further their business interests. Economists use the term "regulatory capture" to describe... View Details
- September 2013 (Revised August 2014)
- Case
Claritas Genomics
By: Robert F. Higgins and Matthew Preble
Claritas Genomics was formed in January 2013 when BCH spun out its Genetics Diagnostic Lab into a fully commercial entity. Claritas offered over 100 genomic tests to detect a range of conditions, including autism and intellectual disabilities, and was developing new... View Details
Keywords: Boston Children's Hospital; Genetic Engineering; Genetically Modified; Genetics Diagnostics; Health Care Industry; Healthcare IT; Healthcare Technology; Healthcare Ventures; Biomedical Research; Patrice Milos; Genomics; Genomic Testing; Life Technologies; Health Care and Treatment; Information Technology; Information Management; Genetics; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Boston; Massachusetts; United States
Higgins, Robert F., and Matthew Preble. "Claritas Genomics." Harvard Business School Case 814-032, September 2013. (Revised August 2014.)
- September 2008
- Background Note
Background on the Technology of Molecular Diagnostics
By: Regina E. Herzlinger and Jason Sanders
To be used as background reading for the "EXACT Sciences Corp.: Commercializing a Diagnostic Test" and "Diagnostic Genomics" cases, HBS nos. 308-090 and 309-040. View Details
Herzlinger, Regina E., and Jason Sanders. "Background on the Technology of Molecular Diagnostics." Harvard Business School Background Note 309-050, September 2008.
- Aug 2011 - 2011
- Conference Presentation
Institutional Heterogeneity, Innovation, and Entrepreneurship in the U.S. Biodiesel Fuel Sector
By: Shon R. Hiatt
- 2011
- Other Unpublished Work
From Farms to Fuel Tanks: Collective Actors and New-Venture Innovation in the U.S. Biodiesel Fuel Sector
By: Shon R. Hiatt
Little is known about the influence of collective actors on innovative technological recombinations by new ventures. Using data from U.S. biodiesel producers, I examine how the efforts of multiple collective actors (farm associations) to promote varying types of... View Details
- 01 Mar 2005
- News
A Primer on Patents
fifteen years ago, as a doctoral candidate in Harvard’s Economics Department, Lerner was collecting data on the role of VC funding in the biotechnology industry. Before long, he also became intrigued by the concept of intellectual... View Details
- 01 Mar 2003
- News
Naina Lal Kidwai
to the global automobile industry. Biotechnology and pharmaceutical firms are emerging as international players. There are also opportunities in infrastructure investment, such as telecom, ports, roads, and airports. Please comment on... View Details